Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07334938 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Far Infrared Rays and Transcutaneous Electrical Nerve Stimulation on Short Term Prognosis of Head and Neck Cancer Patients Receiving Curative Treatment

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study completion date: Dec 30, 2025 to Mar 31, 2026
    • Start date: May 1, 2025 to May 1, 2024
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to determine whether far-infrared therapy and transcutaneous electrical nerve stimulation (TENS) can improve postoperative side effects in patients with head and neck cancer. The main questions this study aims to answer are: Can far-infrared therapy and transcutaneous electrical nerve stimulation reduce pain and improve neck range of motion? Can far-infrared therapy and transcutaneous electrical nerve stimulation reduce inflammation? Researchers will compare three groups: Group A: control group; Group B: transcutaneous electrical nerve stimulation; Group C: far-infrared therapy combined with transcutaneous electrical nerve stimulation, to evaluate differences in pain, neck range of motion, and inflammation. Participants will receive the assigned intervention in the morning and evening for five consecutive days. Outcome measurements will be conducted on the first and fifth days.
Trial Details
NCT Number NCT07334938
Lead Sponsor Buddhist Tzu Chi General Hospital
Conditions
(from sponsor)		 Head and Neck Cancer (H&N)
Related terms Head and Neck Neoplasms
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov